Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature

CONCLUSION: We conclude that reduced HER2 expression by IHC following neoadjuvant treatment was associated with lower recurrence rates in HER2 IHC 3+ breast cancer. If confirmed, RD HER2 IHC expression could be used as a prognostic biomarker to stratify patients in adjuvant trials and identify patients who may benefit from more intensive adjuvant therapy and post therapy surveillance.PMID:37812963 | DOI:10.1016/j.breast.2023.103586

Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: Jan Paredes Mogica Haiming Tang Yuanxin Liang Minghao Zhong Pei Hui Malini Harigopal Uma Krishnamurti Neal A Fischbach Haiying Zhan Source Type: research